ScreenerHero

KPTI Karyopharm Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · karyopharm.com
0.6450USD-0.75%Mkt Cap: 14.63M $P/E: —

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap14.63M USD
Enterprise Value278.17M USD
Revenue (TTM)146.62M USD
Gross Profit140.12M USD
Net Income (TTM)-196.04M USD
Revenue/Share7.55 USD
Last Price0.6450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees228
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.23
PEG—
EV/EBITDA-3.38
EV/Revenue1.90
P/S0.10
P/B-0.04
EPS (TTM)-14.33
EPS (Forward)-2.82
52W Range
0.62580% of range10.99
52W High10.99 USD
52W Low0.6258 USD
Profitability
Gross Margin95.93%
Oper. Margin-67.38%
EBITDA Margin-56.06%
Profit Margin-134.21%
ROE66.92%
ROA-180.82%
Growth
Revenue Growth-11.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.37M USD
CapEx (TTM)—
FCF Margin-20.24%
FCF Yield-202.84%
Net Debt263.42M USD
Net Debt/EBITDA-3.20
Balance Sheet
Debt/Equity-0.80
Current Ratio0.79
Quick Ratio0.71
Book Value/Sh-14.56 USD
Cash/Share2.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateFeb 26, 2025
Analyst Consensus
Rating—
Target (Mean)7.250 USD
Upside (mean)+1024.0%
Target Range3.000 USD – 11.00 USD
3.000+1024.0% to mean11.00
# Analysts4
Ownership
Shares Out.22.68M
Float16.01M
Insiders4.67%
Institutions97.03%
Short Interest
Short Ratio6.0d
Short % Float34.85%
Short % Out.34.68%
Shares Short7.87M
Short (prev mo.)9.64M
Technical
SMA 502.172 (-70.3%)
SMA 2006.690 (-90.4%)
Beta1.04
S&P 52W Chg16.45%
Avg Vol (30d)1.39M
Avg Vol (10d)1.50M
Technical Indicators
RSI (14)16.9
MACD-0.5680
MACD Signal-0.5786
MACD Hist.+0.0106
BB Upper2.284 USD
BB Middle1.406 USD
BB Lower0.5280 USD
BB Width124.89%
ATR (14)0.2147 USD
Vol Ratio (20d)0.46x